(Q34589333)

3 August 2017

Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers (English)

1 reference

3 August 2017

1 reference

Samantha Abel

1

1 reference

3 August 2017

Timothy M Jenkins

2

1 reference

3 August 2017

Lyndsey A Whitlock

3

1 reference

3 August 2017

Caroline E Ridgway

4

1 reference

3 August 2017

Gary J Muirhead

5

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 April 2008

1 reference

British Journal of Clinical Pharmacology

3 August 2017

1 reference

3 August 2017

65 Suppl 1

1 reference

3 August 2017

38-46

1 reference

Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers

3 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2311410

Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2311410

Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2311410

Role of P-glycoprotein in pharmacokinetics: clinical implications

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2311410

Management of drug interactions in patients with HIV.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2311410

Coreceptors--Implications for HIV Pathogenesis and Therapy

7 July 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2311410

7 July 2018

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2008.03134.X

Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2008.03134.X

Rifampicin, a keystone inducer of drug metabolism: from Herbert Remmer's pioneering ideas to modern concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2008.03134.X

Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2008.03134.X

Mechanism-based inactivation of CYP3A by HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2008.03134.X

Effect of efavirenz on intestinal p-glycoprotein and hepatic p450 function in rats

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2311410

10.1111/J.1365-2125.2008.03134.X

27 October 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference

3 August 2017

1 reference